Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
FGFR2
Name:
fibroblast growth factor receptor 2
Location:
10q26.13
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT02450123 | Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib in Subjects With RET Fusion Positive or FGFR2 Amplification Refractory Solid Tumors | View | |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | View | |
| NCT04507503 | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | View | |
| NCT05859477 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | View | |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced andor Metastatic Endometrial Cancer | View | |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | View | |
| NCT01752920 | Phase 12 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | View | |
| NCT02691767 | Study to Evaluate the Safety and Efficacy of Pazopanib in Subject With Refractory Solid Tumors | View | |
| NCT02691793 | Study to Evaluate the Safety and Efficacy of Sunitinib in Subject With Refractory Solid Tumors | View | |
| NCT01244438 | Study of FP-1039 in Subjects With Endometrial Cancers | View | |
| NCT02450136 | Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib in Subjects With FGFR2 Amplification FGFR2 Mutation Refractory Solid Tumors | View | |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer | View | |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | View | |
| NCT01719549 | Dovitinib for Gastric Cancer With FGFR2 Amplification GASDOVI-1 | View | |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | View | |
| NCT01881217 | First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced Refractory Solid Tumors | View | |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations | View | |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma | View | |
| NCT02150967 | A Phase II Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | View | |
| NCT02265341 | Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions | View | |
| NCT02318329 | Open-Label Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | View | |
| NCT02331966 | Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia | View | |
| NCT04071184 | Study of Alofanib in Patients With Metastatic Gastric Cancer | View | |
| NCT02368951 | Phase I Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 FGFR2 | View | |
| NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | View | |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - FIGHT-202 | View | |
| NCT03773302 | Phase 3 Study of BGJ398 Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene FusionsTranslocations | View | |
| NCT03838458 | Molecular and Structural Comparison of Hypospadic and Normal Children Prepuces | View | |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- FUZE Clinical Trial | View | |
| NCT04093362 | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | View | |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | View | |
| NCT04189445 | Futibatinib in Patients With Specific FGFR Aberrations | View | |
| NCT04238715 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor FGFR 2 Gene Fusion | View | |
| NCT04256980 | Pemigatinib in Treating Patients With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | View | |
| NCT04353375 | Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | View | |
| NCT04526106 | REFOCUS a First-in-Human Study of Highly Selective FGFR2 Inhibitor RLY-4008 in Patients with ICC and Other Advanced Solid Tumors | View | |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel Ramucirumab or Atezolizumab in Gastric Adenocarcinoma | View | |
| NCT04972253 | Phase I BLASST-3 Trial | View | |
| NCT05039892 | Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | View | |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 FusionsRearrangements | View | |
| NCT06378593 | A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | View | |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 andor FGFR3 Gene Alterations | View | |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 FusionRearrangements | View | |
| NCT02341326 | Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD | View | |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | View | |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | View | |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | View | |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355 an EcDNA-directed Therapy ecDTx in Subjects with Tumors with Oncogene Amplifications | View | |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | View | |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | View | |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | View | |
| NCT06287918 | A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | View | |
| NCT06439485 | Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | View | |
| NCT02272998 | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes FGFR1 FGFR2 FGFR3 FGFR4 RET KIT | View | |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionAmplification | View | |
| NCT05514912 | Preoperative Nab-paclitaxel Cisplatin and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma The OPTIC Trial | View | |
| NCT02491840 | Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas a Pilot Study | View | |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | View |